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Hypercalcaemia is common in malignant disease and compli-
cates approximately 5-10% of all cancers. Hypercalcaemia
may arise as a result of direct infiltration of bone, by local
osteolysis or indirectly as a result of a humoral mechanism.
In recent years there have been significant advances in our
understanding of the biochemical processes that cause hyper-
calcaemia in malignancy, such that the factors involved in
local osteolysis and in the evolution of humoral hypercal-
caemia have now been delineated.
A number of different cytokines have been implicated in
the development of hypercalcaemia as a result of local
osteolysis. These osteoclast activating factors which are
released locally by metastatic tumour and stimulate osteo-
clastic resorption of bone, include prostaglandin E2 (Greaves
et al., 1980), interleukin 1, (Dewhirst et al., 1985), tumour
necrosis factors alpha (cachectin) (Tashjian et al., 1987) and
beta (lymphotoxin) (Bertolini et al., 1986), epidermal growth
factor (Lorenzo et al., 1986) and transforming growth factor
beta (Sato et al., 1989). It is probable that interleukin 1,
epidermal growth factor and the tumour necrosis factors are
the most important of these aetiological agents as the release
of macrophage colony stimulating factor by osteoblasts is
enhanced by these factors (Felix et al., 1989). Since osteo-
clasts are derived from a haematopoietic stem cell progenitor,
this release of macrophage colony stimulating factor may be
fundamental to osteoclastic bone resorption.
Humoral hypercalcaemia was described in 1941 by Al-
bright, but it has only been within the past 2 years that the
humoral factor causing hypercalcaemia has been charac-
terised. In the 1970s hypercalcaemia was thought to result
from the ectopic production of parathyroid hormone (Mundy
et al., 1984) but this hypothesis remained unproven because
parathyroid hormone antisera failed to demonstrate excessive
secretion of parathyroid hormone in patients with humoral
hypercalcaemia (Goltzman et al., 1981). In addition, low
serum concentrations of 1,25 vitamin D3, bone resorption
and urinary cyclic AMP levels failed to reflect excess
parathyroid hormone activity (Rosol & Capen, 1988) and no
parathyroid hormone mRNA was found in the tumours of
patients with humoral hypercalcaemia (Simpson et al., 1983).
Recently, a peptide derived from human tumours
associated with humoral hypercalcaemia has been sequenced
(Burtis et al., 1987 Moseley et al., 1987). Polyadenylated
RNA from a renal carcinoma from a patient with this syn-
drome was used to construct a cDNA library which was
screened with a codon-preference oligonucleotide, synthesised
on the basis of a partial N-terminal amino acid sequence
from a human tumour derived peptide and a 2.0 kilobase
cDNA was identified. The cDNA encoded a 177 amino acid
prohormone which consisted of a 36 amino acid leader
sequence that is cleaved to produce a 141 amino acid, mature
peptide, parathyroid hormone related peptide. The first 13
amino acids of the mature peptide have sequence homology
with parathyroid hormone, and the N-terminal sequence is
thought to be the parathyroid hormone receptor binding
region (Habener et al., 1984). Parathyroid hormone related
peptide was found to be expressed in most normal human
tissue where its role is undetermined (Mangin et al., 1988).
The gene for parathyroid hormone related peptide has been
mapped to the short arm of chromosome 12 and this is in
contrast to the parathyroid hormone gene which has been
mapped to the short arm of chromosome 11 (Mangin et al.,
1989). The gene for parathyroid hormone related peptide is
complex and contains a six exon, 12 kilobase, single copy
sequence, encoding up to five mRNA species. Exons 2, 3 and
4 are similar to the parathyroid hormone gene (Mangin et
al., 1989).
A recently developed radioimmunoassay for parathyroid
hormone related peptide was used to screen patients with
hypercalcaemia associated malignancy and the results con-
trasted with patients who were normocalcaemic and had
malignant disease, patients with primary hyper-
parathyroidism and normal controls. Parathyroid hormone
related peptide was elevated in 19 of 39 (49%) patients with
malignant hypercalcaemia, 12 of 74 (16%) of normocal-
caemic patients with malignancy, four of 20 patients (20%)
with hyperparathyroidism, but in none of 22 normal controls
(Henderson et al., 1989).
We have treated a patient with humoral hypercalcaemia
associated with a phaeochromocytoma. In this patient,
hypercalcaemia was related to elevated levels of parathyroid
hormone related peptide. Treatment with diphosphonates
failed to result in normocalcaemia. Treatment with octreo-
tide, a somatostatin analogue, resulted in normocalcaemia
consequent to a reduction in serum parathyroid hormone
related peptide levels (Harrison et al., 1990). The response
was transitory, but may provide an insight into the
regulatory control of hypercalcaemia in malignant disease,
and suggests potential future therapeutic manoeuvres.
As a result of scientific advances, parathyroid hormone
related peptide has been clearly established as an important
mechanism for malignant hypercalcaemia, pointing the way
to new approaches. to the treatment of this condition.
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